{
  "pmcid": "12312237",
  "abstract": "300-word version:\n\nTitle: Randomised Controlled Trial to Determine the Maximum Effective Volume of 0.25% Ropivacaine for Superior Trunk Block in Shoulder Arthroscopy\n\nBackground: Superior trunk block (STB) offers a potential alternative to interscalene block (ISB) for shoulder arthroscopy, reducing the risk of hemidiaphragmatic paralysis (HDP) while maintaining analgesic efficacy. This study aimed to determine the maximum effective volume (MEV90) of 0.25% ropivacaine to prevent HDP in 90% of patients.\n\nMethods: This prospective, randomised controlled trial was conducted at Changzheng Hospital. Participants were adults aged 46-80 years, ASA I-III, scheduled for shoulder arthroscopy. Exclusion criteria included respiratory comorbidities. A biased coin design was used for volume assignment, with randomisation and allocation concealment achieved through sealed envelopes. The primary outcome was HDP occurrence, assessed 3 hours post-block. Blinding was maintained for outcome assessors, patients, and clinicians.\n\nResults: Fifty-two patients were randomised and analysed. The MEV90 of 0.25% ropivacaine for ultrasound-guided STB was estimated at 7.6 mL (95% CI: 6.5â€“8.5 mL) using isotonic regression. Sensory block duration varied with volume, with no adverse events reported.\n\nInterpretation: The study identified 7.6 mL as the MEV90 of 0.25% ropivacaine for STB, providing a diaphragm-sparing alternative for patients undergoing shoulder arthroscopy. This volume threshold is particularly advantageous for high-risk respiratory patients, offering optimal pulmonary function preservation.\n\nTrial registration: Chinese Clinical Trial Registry (ChiCTR2200059042); first registered 23/04/2022.\n\nFunding: Not specified.",
  "word_count": 223
}